JP Nadda reiterates the importance of pharmacovigilance
Noting considerable changes in the medicine consumption in India, Union Health Miniter, JP Nadda has reinstated the objective and importance of setting up pharmacovigilance-to monitor the adverse effects of drugs in the country.
"Considerable progress has been made by the India Pharmacovigilance Programme over the last few years, including setting up of pharmacovigilance system in tuberculosis and HIV-AIDS related public health programmes," he said after inaugrating the 38th annual meeting of National Pharmacovigilance Centres.
Nadda is optimistic on the progress made by the government in the field in the last five years, after the pharmacovigilance programme was launched in the year 2010. Now, the unit is spread across the country with 179 centres operating in India.
Adverse drug reactions are reported to Indian Pharmacopoeia Commission, which works in collaboration with global Adverse Drug Reaction Monitoring Centre, Sweden to contribute to the global Adverse Drug Reactions data base, Nadda said.
Health Secretary BP Sharma said the importance of Pharmacovigilance has increased as there have been changes in the ways people take medicines.
"People prescribe medicines from across the border through Internet and all kinds of medicines are coming for which we are not sure whether they are fully tested. They might be coming from places which may not be having a strong regulatory system. People are also taking self-medication, then there also counterfiet and substandard medication also. In such situation the need for a pharmacovigilance system is very important," Sharma said.
Organized by WHO, the aims of the meeting is to provide a platform to representatives of Pharmacovigilance Centers from around the world to meet and discuss on co-vigilance and drug safety issues.
At the conclusion of the meeting, the representatives will give recommendation to WHO on how to address the problems of co-vigilance and patient safety globally.
"Considerable progress has been made by the India Pharmacovigilance Programme over the last few years, including setting up of pharmacovigilance system in tuberculosis and HIV-AIDS related public health programmes," he said after inaugrating the 38th annual meeting of National Pharmacovigilance Centres.
Nadda is optimistic on the progress made by the government in the field in the last five years, after the pharmacovigilance programme was launched in the year 2010. Now, the unit is spread across the country with 179 centres operating in India.
Adverse drug reactions are reported to Indian Pharmacopoeia Commission, which works in collaboration with global Adverse Drug Reaction Monitoring Centre, Sweden to contribute to the global Adverse Drug Reactions data base, Nadda said.
Health Secretary BP Sharma said the importance of Pharmacovigilance has increased as there have been changes in the ways people take medicines.
"People prescribe medicines from across the border through Internet and all kinds of medicines are coming for which we are not sure whether they are fully tested. They might be coming from places which may not be having a strong regulatory system. People are also taking self-medication, then there also counterfiet and substandard medication also. In such situation the need for a pharmacovigilance system is very important," Sharma said.
Organized by WHO, the aims of the meeting is to provide a platform to representatives of Pharmacovigilance Centers from around the world to meet and discuss on co-vigilance and drug safety issues.
At the conclusion of the meeting, the representatives will give recommendation to WHO on how to address the problems of co-vigilance and patient safety globally.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.